The United States Food and Drugs Administration (USFDA) has given final approval to Zydus Lifesciences to market Febuxostat tablets, 40 mg and 80 mg, according to a statement from Zydus.

Febuxostat tablets are indicated to lower hyperuricemia (high uric acid in the blood) in patients with gout who have been treated with allopurinol that did not work well or cannot be treated with allopurinol.

The drug will be manufactured at the formulation manufacturing facility of Zydus at Moraiya, Ahmedabad, the statement said.

Other drugs approval by USFDA

USFDA gives approval for Prasugrel tablets

USFDA approves Fesoterodine Fumarate Extended-Release tablets

USFDA gives final approval for this Insomnia drug

USFDA approves this monoclonal antibody to treat multiple sclerosis

USFDA gives final approval to this breast cancer injection

USFDA gives approval for Fulvestrant injection

Sale of coronary stents: High Court seeks stand of Centre and NPPA

USFDA gives approval for Prasugrel tablets

IPC publishes draft monograph revision proposals

High demand for Indian generic drugs in China

Govt Job: For the post of Director at CDTL, CDSCO

List of approved FDCs (Fixed Dose Combinations) Updated

List of approved New Drugs Updated

NPPA extends ceiling price of LMO, Oxygen Inhalation

Drug licences of these two firms suspended: FDA Manipur

Latest Notifications regarding Pharmaceutical
https://thehealthmaster.com/2023/01/12/usfda-gives-approval-for-febuxostat-tablets/